DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy ; volume:23 ; number:1 ; day:10 ; month:5 ; year:2024 ; pages:1-5 ; date:12.2024
Molecular cancer ; 23, Heft 1 (10.5.2024), 1-5, 12.2024

Creator
Su, Po-Lan
Chakravarthy, Karthik
Furuya, Naoki
Brownstein, Jeremy
Yu, Jianhua
Long, Meixiao
Carbone, David
Li, Zihai
He, Kai
Contributor
SpringerLink (Online service)

DOI
10.1186/s12943-024-02012-z
URN
urn:nbn:de:101:1-2407220950221.748191604602
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:03 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Su, Po-Lan
  • Chakravarthy, Karthik
  • Furuya, Naoki
  • Brownstein, Jeremy
  • Yu, Jianhua
  • Long, Meixiao
  • Carbone, David
  • Li, Zihai
  • He, Kai
  • SpringerLink (Online service)

Other Objects (12)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

The First FDA-Approved Antibody-Drug Conjugate

The First FDA-Approved Antibody-Drug Conjugate

Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

Related objects